Calidad de vida de pacientes con cáncer de próstata. Estudio prospectivo mediante la aplicación cuestionario CAVIPRES

1. SIERRA CR, SÁNCHEZ D, DE PABLO A. Calidad de vida de pacientes con cáncer de próstata en tratamiento con bloqueo androgénico continuo vs intermitente. Estudio prospectivo mediante la aplicación del cuestionario CAVIPRES. An Sist Sanit Navar 2015; 38: 193-202.

https://doi.org/10.4321/S1137-66272015000200003

2. ACQUADRO C, BERZON R, DUBOIS D, LEIDY NK, MARQUIS P, REVICKI D et al. PRO Harmonization Group. Incorporating the patient's perspective into drug development and communi¬cation: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003; 6: 522-531.

https://doi.org/10.1046/j.1524-4733.2003.65309.x

3. FAYERS P, MACHIN D. Quality of Life. 2nd ed. Chichester: John Wiley and Sons, 2007.

https://doi.org/10.1002/9780470024522

4. ALLAN CA, COLLINS VR, FRYDENBERG M, MCLACHLAN RI, MATTHIESSON KL. Androgen deprivation therapy complications. Endocr Relat Cancer 2014; 21: 119-129.

https://doi.org/10.1530/ERC-13-0467

5. BOURKE L, SOHANPAL R, NANTON V, CRANK H, ROSARIO DJ, SAXTON JM. A qualitative study evaluating experiences of a lifestyle intervention in men with prostate cancer undergoing androgen suppression therapy. Trials 2012; 14: 208.

https://doi.org/10.1186/1745-6215-13-208

6. GÓMEZ F, COZAR J, GÜNTHNER S, PUYOL M, SILMI A, BARÓ E et al. Desarrollo y validación del primer cuestionario español de calidad de vida en pacientes con cáncer de próstata, basado en la percepción del paciente. Actas Urol Esp 2009; 33: 623-634.

https://doi.org/10.1016/S0210-4806(09)74200-7

7. AARONSON NK, CULL A, KAASA S, SPRANGERS M. The EORTC modular approach to quality of life assessment in Oncology. Int J Ment Health 1994; 23: 75-96.

https://doi.org/10.1080/00207411.1994.11449284

8. ARRARÁS JI, ARIAS F, ILLARRAMENDI JJ, MANTEROLA A, SALGADO E, DOMÍNGUEZ MA et al. Calidad de vida relacionada con la salud en los servicios de Oncología del Hospital de Navarra. Grupo de calidad de vida de la EORTC. An Sist Sanit Navar 2011; 34: 9-20.

https://doi.org/10.4321/S1137-66272011000100002

9. DENHAM JW, JOSEPH D, LAMB DS, SPRY NA, DUCHESNE G, MATTHEWS J et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol 2014; 15: 1076-1089.

https://doi.org/10.1016/S1470-2045(14)70328-6

10. CROOK JM, O'CALLAGHAN CJ, DUNCAN G, DEARNALEY DP, HIGANO CS, HORWITZ EM et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367: 895-903.

https://doi.org/10.1056/NEJMoa1201546

11. DENHAM JW, WILCOX C, JOSEPH D, SPRY NA, LAMB DS, TAI KH et al. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol 2012; 13: 1260-1270.

https://doi.org/10.1016/S1470-2045(12)70423-0

12. GALVÃO DA, TAAFFE DR, SPRY N, JOSEPH D, NEWTON RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010; 28: 340-347.

https://doi.org/10.1200/JCO.2009.23.2488

13. GALVÃO DA, SPRY N, DENHAM J, TAAFFE D, CORMIE P, JOSEPH D et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014; 65: 856-864.

https://doi.org/10.1016/j.eururo.2013.09.041